[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation
References (15)
- et al.
Bailliére's Clinical Endocrinology and Metabolism
(1990) - et al.
Lancet
(1989) - et al.
Life Sci
(1982) - et al.
Life Sci
(1981) Life Sci
(1985)- et al.
Life Sci
(1991) - et al.
J Clin Endocrinol Metab
(1990)
There are more references available in the full text version of this article.
Cited by (334)
Positron emission tomography and single-photon emission computed tomography physics
2022, Handbook of Neuro-Oncology NeuroimagingImaging the immune cell in immunotherapy
2022, NK Cells in Cancer Immunotherapy: Successes and ChallengesThe impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors
2021, Molecular and Cellular EndocrinologyMetallic radionuclides for diagnostic imaging and cancer radiotherapy: The development of theragnostic matched pairs and targeted alpha therapy
2021, Advances in Inorganic ChemistryThe emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy
2021, Nuclear Medicine and BiologyStructural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging
2020, Bioorganic Chemistry
Copyright © 1991 Published by Elsevier Inc.